Browse > Article
http://dx.doi.org/10.13160/ricns.2016.9.3.190

Comparative Molecular Similarity Index Analysis on 2-(indol-5-yl)thiazolederivatives as Xanthine Oxidase(XO)inhibitors  

Nagarajan, Santhosh Kumar (Department of Genetic Engineering, School of Bioengineering, SRM University)
Madhavan, Thirumurthy (Department of Genetic Engineering, School of Bioengineering, SRM University)
Publication Information
Journal of Integrative Natural Science / v.9, no.3, 2016 , pp. 190-198 More about this Journal
Abstract
Xanthine Oxidase is an enzyme, which oxidizes hypoxanthine to xanthine, and xanthine to uric acid. It is widely distributed throughout various organsincluding the liver, gut, lung, kidney, heart, brain and plasma. It is involved in gout pathogenesis. In this study, we have performed Comparative Molecular Field Analysis (CoMSIA) on a series of 2-(indol-5-yl) thiazole derivatives as xanthine oxidase (XO) inhibitors to identify the structural variations with their inhibitory activities. Ligand based CoMSIA models were generated based on atom-by-atom matching alignment. In atom-by-atom matching, the bioactive conformation of highly active molecule 11 was generated using systematic search. Compounds were aligned using the bioactive conformation and it is used for model generation. Different CoMSIA models were generated using different alignments and the best model yielded across-validated $q^2$ of 0.698 with five components and non-cross-validated correlation coefficient ($r^2$) of 0.992 with Fisher value as 236.431, and an estimated standard error of 0.068. The predictive ability of the best CoMSIA models was found to be $r{^2}_{pred}$ 0.653. The study revealed the important structural features required for the biological activity of the inhibitors and could provide useful for the designing of novel and potent drugs for the inhibition of Xanthine oxidase.
Keywords
Xanthine Oxidase; Gout; 3D-QSAR; CoMSIA;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 N. Santhosh Kumar and M. Thirumurthy, "3D-QSAR Studies on 2-(indol-5-yl)thiazole Derivatives as Xanthine Oxidase (XO) Inhibitors", J. Chosun Natural Sci., Vol. 8, pp. 258-266, 2015.   DOI
2 P. Pacher, A. Nivorozhkin, and C. Szabo, "Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol", Pharmacol. Rev., Vol. 58, pp. 87-114, 2006.   DOI
3 D. A. Parks and D. N. Granger, "Xanthine oxidase: biochemistry, distribution and physiology", Acta Physiologica Scandinavica. Supplementum, Vol. 548, pp. 87-99, 1986.
4 M. Cicoira, L. Zanolla, A. Rossi, G. Golia, L. Franceschini, G. Brighetti, P. Zeni, and P. Zardini, "Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy", Am. Heart J., Vol. 143, pp. 1107-1111, 2002.   DOI
5 K. D. Pfeffer, T. P. Huecksteadt, and J. R. Hoidal, "Xanthine dehydrogenase and xanthine oxidase activity and gene expression in renal epithelial cells. Cytokine and steroid regulation", J. Immunol., Vol. 153, pp. 1789-1797, 1994.
6 R. Guerciolini, C. Szumlanski, and R. M. Weinshilboum, "Human liver xanthine oxidase: nature and extent of individual variation", Clin. Pharmacol. Ther., Vol. 50, pp. 663-672, 1991.   DOI
7 R Harrison, "Structure and function of xanthine oxidoreductase: where are we now?", Free Radical Biol. Med., Vol. 33, pp. 774-797, 2002.   DOI
8 R Harrison, "Physiological roles of xanthine oxidoreductase", Drug Metab. Rev., Vol. 36, pp. 363-375, 2004.   DOI
9 H. M. Kramer and G. Curhan, "The association between gout and nephrolithiasis: the national health and nutrition examination survey III, 1988-1994", Am. J. Kidney Dis., Vol. 40, pp. 37-42, 2002.   DOI
10 H. K. Choi and G. Curhan, "Gout: epidemiology and lifestyle choices", Curr. Opin. Rheumatol., Vol. 17, pp. 341-345, 2005.
11 R. L. Wortmann, "Recent advances in the management of gout and hyperuricemia", Curr. Opin. Rheumatol., Vol. 17, pp. 319-324, 2005.   DOI
12 J. George and A. D. Struthers, "The role of urate and xanthine oxidase inhibitors in cardiovascular disease", Cardiovasc. Ther., Vol. 26, pp. 59-64, 2008.
13 N. Dalbeth and L. Stamp, "Allopurinol Dosing in Renal Impairment: Walking the Tightrope Between Adequate Urate Lowering and Adverse Events", Semin. Dialysis, Vol. 20, pp. 391-395, 2007.   DOI
14 K. Abe, H. Shimokawa, K. Morikawa, T. Uwatoku, K. Oi, Y. Matsumoto, T. Hattori, Y. Nakashima, K. Kaibuchi, K. Sueishi, and A. Takeshit, "Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats", Circ. Res., 94: 385-393, 2004.   DOI
15 T.-F. Tsai and T.-Y. Yeh, "Allopurinol in dermatology", Am. J. Clin. Dermatol., Vol. 11, pp. 225-232, 2010.   DOI
16 B. L. Love, R. Barrons, A. Veverka, and K. M. Snider, "Urate-lowering therapy for gout: focus on febuxostat", Pharmacotherapy, Vol. 30, pp. 594-608, 2010.   DOI
17 J. U. Song, S. P. Choi, T. H. Kim, C.-K. Jung, J.-Y. Lee, S.-H. Jung, and G. T. Kim, "Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors", Bioorg. Med. Chem. Lett., Vol. 25, pp. 1254-1258, 2015.   DOI
18 T. Ishizaki, M. Uehata, I. Tamechika, J. Keel, K. Nonomura, M. Maekawa, and S. Narumiya, "Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases", Mol. Pharmacol., Vol. 57, pp. 976-983, 2000.
19 P. Geladi and B. Kowalski, "Partial least-squares regression: a tutorial", Anal. Chim. Acta, Vol. 185, pp. 1-17, 1986.   DOI
20 S. Wold, "Cross-validatory estimation of the number of components in factor and principal components models", Technometrics, Vol. 20, pp. 397-405, 1978.   DOI